EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

by Riley Nolan | Jun 22, 2021

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

by Annie De Groot | Aug 2, 2019

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models
Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

by Annie De Groot | May 14, 2019

EpiVax_Oncology_NYAS_08May19_35Wx25H
Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

by Annie De Groot | Apr 8, 2019

EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h
Integrated Approaches for Design of Precision Cancer Immunotherapies: Selection of Class I and Class II T cell Neo-Epitopes and Removal Treg Epitopes

Integrated Approaches for Design of Precision Cancer Immunotherapies: Selection of Class I and Class II T cell Neo-Epitopes and Removal Treg Epitopes

by Annie De Groot | Mar 1, 2019

2018 Design of Cancer Immunotherapies – Selection of Neo-Epitopes, Removal of Tregitopes
« Older Entries

Recent Posts

  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
  • Throw Down a Challenge
  • EpiVax Birthday Cake Alert! | Fall ’23 Travel Schedule
  • Lab Day at the Beach 2023 *Pictures!*
  • High Throughput Immunogenicity Analysis

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562